Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 September 2021 | Story Lacea Loader | Photo Supplied
Mr David Noko, newly appointed Chairperson of the UFS Council.

During its third scheduled meeting for the year that took place virtually on 17 September 2021, the Council of the University of the Free State (UFS) appointed Mr David Noko as Chairperson for a term of four years, as from 1 October 2021.

Mr Noko, who was Deputy Chairperson of the Council, will take over the Chairpersonship from Dr Willem Louw, whose term will come to an end on 30 September 2021.
 
“On behalf of the Council, I congratulate Mr Noko and wish him all the best during his term of leading the Council of the UFS. With the skills and competence available in the Council, complemented by Prof Francis Petersen, Rector and Vice-Chancellor, and his team, he has access to a formidable group of individuals to support him in the execution of this very important role,” said Dr Louw during the meeting. 
 
“I am humbled and honoured for the opportunity and thank the Council for their confidence and trust in me. Since serving on the Council, I have become an ambassador of the University of the Free State, talking to many stakeholders about the institution and how much it should be supported. I am here to serve and look forward to doing so in a professional and dignified manner, together with everyone on the Council and with the leadership of the university,” said Mr Noko.
 
Mr Noko is well-known and respected internationally as a business leader. He has a National Higher Diploma in Mechanical Engineering from the Technikon Witwatersrand (now the University of Johannesburg), a Management Development Programme (MDP) Certificate from the University of the Witwatersrand, and a Postgraduate Diploma in Company Directorships from the Graduate Institute of Management and Technology. He also completed a master’s degree in Business Administration at the Heriot-Watt University and a Senior Executive Programme at the London Business School.
 
Before retiring from the corporate world in 2019, Mr Noko was the Executive Vice-President of AngloGold Ashanti, where he was responsible for the company’s global Sustainable Development and Government Relations portfolios. His career began at the General Electric Company (GEC) before moving to South African Breweries in 1987, and then to Pepsi-Cola International in 1994, where he gained extensive international exposure and global experience.
 
In 1999, Mr Noko was appointed as Chief Executive Officer (CEO) of Air Chefs (Pty) Ltd in South Africa, before joining De Beers in 2002. In 2006, he was appointed Managing Director and CEO of De Beers Consolidated Mines Limited (DBCM), and in 2010 he founded his own company, CelaCorp (Pty) Ltd. He also founded ESG Advisory (Pty) Ltd, a company providing advisory services to corporates relating to environment, social and governance matters, mostly focusing on mining companies.
 
He is a member of the Institute of Directors SA and served on the boards of Royal Bafokeng Platinum Limited, Harmony Gold (Deputy Chairman), AstraPak Ltd, and PlatiStone Holdings (Chairman). He is currently a board director of African Rainbow Minerals Ltd, Tongaat Hulett Ltd, and Aveng Moolmans (Pty) Ltd.

The Council also thanked Dr Louw for his service and for the impeccable leadership he displayed during the time he served.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept